Semaglutide

四川多瑞药业

2025-05-22

US FDA Registration No.: 043251

Indication: Type Ⅱdiabetes, Obesity

Features:
Purity ≥ 99.0%,  individual impurity ≤ 0.1%
Meets the quality requirements for oral tablets and injections
Status: Validation Production Complete  

Batch Size: 15kg

Prev:

Tirzepatide

Next:

Retatrutide